Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis
Objective To examine the prevalence of side effects with methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) among patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Methods This retrospective analysis, conducted between January 2000 and January 2019, used data from th...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11467 |
| _version_ | 1798017979000029184 |
|---|---|
| author | Alexis Ogdie Ervant J. Maksabedian Hernandez Yomei Shaw Bradley Stolshek Kaleb Michaud |
| author_facet | Alexis Ogdie Ervant J. Maksabedian Hernandez Yomei Shaw Bradley Stolshek Kaleb Michaud |
| author_sort | Alexis Ogdie |
| collection | DOAJ |
| description | Objective To examine the prevalence of side effects with methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) among patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Methods This retrospective analysis, conducted between January 2000 and January 2019, used data from the FORWARD databank. Adult patients enrolled in the registry with self‐reported and physician‐confirmed diagnosis of PsA or RA were included if they had completed at least one questionnaire before initiating and within 12 months following initiation of MTX or a TNFi. The primary outcome was to examine the prevalence of side effects with MTX and TNFi within the year following treatment initiation. Multivariate logistic regression analysis was performed to examine the association between PsA and RA and the reporting of their side effects. Results Overall, 116 patients with PsA and 4247 patients with RA newly initiated MTX, and 124 patients with PsA and 4361 patients with RA newly initiated a TNFi. Patients with PsA were more likely to report MTX‐related side effects than those with RA (44.8% vs. 29.4%), whereas similar proportions of patients with PsA and RA reported TNFi‐related side effects within the first year (24.2% and 22.8%, respectively). Additionally, patients with PsA initiating MTX were more likely to report nausea, vomiting, abdominal pain, depression, and tinnitus than patients with RA initiating MTX or those with PsA or RA initiating a TNFi. Conclusion Patients with PsA reported more side effects than patients with RA, and this difference was more pronounced in those receiving MTX versus TNFi. |
| first_indexed | 2024-04-11T16:16:25Z |
| format | Article |
| id | doaj.art-5f4e2603aa51450eae784b03803f6fe5 |
| institution | Directory Open Access Journal |
| issn | 2578-5745 |
| language | English |
| last_indexed | 2024-04-11T16:16:25Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | ACR Open Rheumatology |
| spelling | doaj.art-5f4e2603aa51450eae784b03803f6fe52022-12-22T04:14:30ZengWileyACR Open Rheumatology2578-57452022-11-0141193594110.1002/acr2.11467Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid ArthritisAlexis Ogdie0Ervant J. Maksabedian Hernandez1Yomei Shaw2Bradley Stolshek3Kaleb Michaud4Hospital of the University of Pennsylvania PhiladelphiaAmgen Inc. Thousand Oaks CaliforniaFORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas, and University of Michigan Ann ArborAmgen Inc. Thousand Oaks CaliforniaFORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas, and University of Nebraska Medical Center OmahaObjective To examine the prevalence of side effects with methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) among patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Methods This retrospective analysis, conducted between January 2000 and January 2019, used data from the FORWARD databank. Adult patients enrolled in the registry with self‐reported and physician‐confirmed diagnosis of PsA or RA were included if they had completed at least one questionnaire before initiating and within 12 months following initiation of MTX or a TNFi. The primary outcome was to examine the prevalence of side effects with MTX and TNFi within the year following treatment initiation. Multivariate logistic regression analysis was performed to examine the association between PsA and RA and the reporting of their side effects. Results Overall, 116 patients with PsA and 4247 patients with RA newly initiated MTX, and 124 patients with PsA and 4361 patients with RA newly initiated a TNFi. Patients with PsA were more likely to report MTX‐related side effects than those with RA (44.8% vs. 29.4%), whereas similar proportions of patients with PsA and RA reported TNFi‐related side effects within the first year (24.2% and 22.8%, respectively). Additionally, patients with PsA initiating MTX were more likely to report nausea, vomiting, abdominal pain, depression, and tinnitus than patients with RA initiating MTX or those with PsA or RA initiating a TNFi. Conclusion Patients with PsA reported more side effects than patients with RA, and this difference was more pronounced in those receiving MTX versus TNFi.https://doi.org/10.1002/acr2.11467 |
| spellingShingle | Alexis Ogdie Ervant J. Maksabedian Hernandez Yomei Shaw Bradley Stolshek Kaleb Michaud Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis ACR Open Rheumatology |
| title | Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis |
| title_full | Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis |
| title_fullStr | Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis |
| title_full_unstemmed | Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis |
| title_short | Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis |
| title_sort | side effects of methotrexate and tumor necrosis factor inhibitors differences in tolerability among patients with psoriatic arthritis and rheumatoid arthritis |
| url | https://doi.org/10.1002/acr2.11467 |
| work_keys_str_mv | AT alexisogdie sideeffectsofmethotrexateandtumornecrosisfactorinhibitorsdifferencesintolerabilityamongpatientswithpsoriaticarthritisandrheumatoidarthritis AT ervantjmaksabedianhernandez sideeffectsofmethotrexateandtumornecrosisfactorinhibitorsdifferencesintolerabilityamongpatientswithpsoriaticarthritisandrheumatoidarthritis AT yomeishaw sideeffectsofmethotrexateandtumornecrosisfactorinhibitorsdifferencesintolerabilityamongpatientswithpsoriaticarthritisandrheumatoidarthritis AT bradleystolshek sideeffectsofmethotrexateandtumornecrosisfactorinhibitorsdifferencesintolerabilityamongpatientswithpsoriaticarthritisandrheumatoidarthritis AT kalebmichaud sideeffectsofmethotrexateandtumornecrosisfactorinhibitorsdifferencesintolerabilityamongpatientswithpsoriaticarthritisandrheumatoidarthritis |